Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 5, 2026CancersOpen Access

Neoadjuvant, Adjuvant and Perioperative Treatment in Early-Stage Non-Small Cell Lung Cancer (NSCLC) with Actionable Genomic Alterations: Current Landscape and Future Perspectives

View Full Paper
Ask AI
Bookmark
Share

Authors

PKProdromos KoutoukoglouGMGiannis Mountzios

Discussion

Loading...

Member takes

Overview

This review summarizes treatment strategies in early-stage NSCLC with genomic alterations, indicating future directions for better outcomes.

Key Points

  • The review addresses current treatments and future approaches for early-stage non-small cell lung cancer with genomic alterations.
  • Reviewed existing literature on neoadjuvant and adjuvant treatments for early-stage NSCLC.
  • Analyzed treatment outcomes associated with various targeted therapies.
  • Explored future management strategies for patients with actionable molecular alterations.
  • Neoadjuvant/adjuvant chemotherapy shows modest benefits in disease-free and overall survival.
  • Immunotherapy combined with chemotherapy significantly improves complete pathological and event-free survival.
  • Targeted therapies like osimertinib and alectinib substantially enhance event-free and overall survival in oncogene-addicted NSCLC.

Cite This Study

Koutoukoglou et al. (2026) studied this question.

synapsesocial.com/papers/6984346ff1d9ada3c1fb2886https://doi.org/10.3390/cancers18030493
View Full Paper
Ask AI
Bookmark
Share